Title of article - Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus.
Abstract
Reactivation of hepatitis B viral infection (HBVr) is a known risk in cancer patients with a history of chronic hepatitis B infection receiving cytotoxic or immunosuppressive therapies. Patients with hematologic malignancies or those who have received stem cell transplantation seem to be most at risk but reactivation has been reported with various malignancies. Reactivation can present as asymptomatic liver function test abnormalities (LFTs), with symptoms of abdominal pain, encephalopathy, or as fulminant hepatitis and liver failure. Here we report the first case of a patient with islet cell tumor on octreotide and sirolimus who developed hepatitis B reactivation with fulminant liver failure and death.
CLICK HERE for Full article Click button above to go to original article link with complete article details for Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus.
Please CLICK HERE to discuss with us on facebook about this article.
Click below for Details of research Institute
Department of Medicine, Memorial Sloan Kettering Cancer Center, Gastroenterology and Nutrition Service, New York, NY 10065, USA.
Details of Journal for Fatal hepatitis B reactivation in a patient with islet cell tumor on octreotide and sirolimus.
Journal Title - Journal of gastrointestinal oncology
ISSN - 2078-6891
Volume - 6
Issue - 5
Publish date - 2015-Oct
Language - eng
Country - China
No comments:
Post a Comment